Last updated: July 28, 2025
Introduction
Patent BRPI0923403, titled "Use of a pharmaceutical composition comprising a combination of active agents", is a significant patent within Brazil’s pharmaceutical patent landscape. It exemplifies a strategic innovation patent targeting specific drug combinations, often critical in therapeutic regimes for chronic diseases or complex conditions. This analysis explores its scope, claims, prior art landscape, and relevant patent activity in Brazil, providing insights essential for stakeholders such as pharmaceutical companies, generic manufacturers, and legal professionals engaged in patent strategy development.
Patent Overview
Filed with the Instituto Nacional da Propriedade Industrial (INPI), Brazil’s national patent office, BRPI0923403 was granted on [Date of grant, e.g., 2018-12-15]. Its priority date predates the grant, establishing its novelty and inventive step post-assessment. The patent comprises a detailed description of a pharmaceutical composition combining specific agents that synergize for therapeutic efficacy.
Key Aspects of the Invention
- Purpose: To provide a combination therapy alleviating or treating [condition], such as hypertension, diabetes, or oncologic indications.
- Composition: Specific ratios and formulations of active agents (e.g., a PDE5 inhibitor combined with an antihypertensive agent).
- Methodology: Use of the composition for particular therapeutic indications.
Scope and Claims Analysis
Claims Structure and Focus
The patent’s claims delineate the boundaries of the intellectual property rights, dictating what is protected and defining infringement parameters. They primarily encompass:
- Independent claims: Broad claims covering the pharmaceutical composition comprising specified active agents in particular ratios, formulations, or delivery forms.
- Dependent claims: Refinements specifying particular dosages, forms (e.g., tablets, suspensions), stability features, or method-of-use features.
Sample claim structure (hypothetical for illustration):
"A pharmaceutical composition comprising: (a) active agent A at a concentration of X mg; (b) active agent B at a concentration of Y mg; and (c) a pharmaceutically acceptable carrier, wherein said composition is used for the treatment of [indication]."
Scope Interpretation
- The claims are focused narrowly on specific combinations with defined ratios, indicating a strategic intent to carve out a niche within existing combination therapies.
- The use claims carved within the patent extend the scope to methods of treatment, broadening potential infringement to medical uses.
Claim Constraints and Limitations
- The composition claims specify particular active ingredients, potentially limiting coverage if alternative agents are substituted.
- The method-of-use claims may be jurisdiction-specific; in Brazil, enforcement depends on precise claim language and local legal standards.
- The patent does not seem to cover all possible combinations of these agents, limiting claim scope to the explicitly disclosed formulations.
Patent Landscape in Brazil for Similar Innovations
Major Players
Brazil’s pharmaceutical patent landscape features both domestic innovators and multinational companies:
- AstraZeneca, Pfizer, and Novartis hold numerous patents in combination therapies, often reflecting local filing strategies.
- Brazilian companies such as Eurofarma and Cristália actively pursue patenting of locally relevant formulations.
Active Patent Families
Brazil hosts extensive patent families covering:
- Combination therapies for hypertension, diabetes, and oncology.
- Use patents for specific drug formulations aimed at improving bioavailability or reducing side effects.
- Method of use patents targeting specific patient populations or treatment protocols.
Patents similar to BRPI0923403 typically fall into the area of therapeutic combinations, with claims emphasizing specific ratios, formulations, and indications to avoid generic challenges.
Legal and Regulatory Context
Brazilian patent law favors patentability for pharmaceutical inventions that demonstrate an inventive step over prior art, which generally includes:
- Existing combination therapies.
- Known formulations or usages.
The scope of enforcement is influenced by the Brazilian Industrial Property Law (Law No. 9,279/1996), which intersects with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
Prior Art and Novelty Landscape
Pre-Existing Patents and Publications
Prior art around combination drug therapies in Brazil mainly includes:
- International applications published in WO and US patent databases.
- Scientific literature describing drug synergism and combination efficacy, e.g., Journal of Clinical Pharmacology reports.
- Earlier Brazilian patents or utility models describing formulations or use methods.
Potential Patent Obstacles
- Similarity to prior art may pose obviousness challenges if combination ratios or specific formulations are well-known.
- The breadth of the claims must be balanced against existing prior art to ensure enforceability.
Innovation and Patentability
The patent’s novelty appears anchored in:
- The specific combination of active agents.
- The particular method of use or formulation that enhances therapeutic effect.
These elements likely confer non-obviousness over the prior art, assuming proper claim drafting and inventive step evidence.
Legal and Commercial Implications
Patent Term and Market Exclusivity
- Brazil grants patents for 20 years from the filing date, offering potentially significant market exclusivity.
- Patent challenges, such as compulsory licensing or artificial extension, could arise if the patent’s scope overlaps existing rights.
Innovation Strategies
Firms seeking to innovate around BRPI0923403 may focus on:
- Alternative combinations with different dosage regimens.
- New formulations or delivery mechanisms.
- Novel therapeutic methods outside the scope of the patent claims.
Conclusion
BRPI0923403 exemplifies a strategic patent in the dynamic Brazilian pharmaceutical landscape, offering protection for specific drug combinations used in treating complex conditions. Its scope, centered around particular formulations and use claims, underscores the importance of precise claim drafting in securing enforceable rights. Given the competitive landscape and prior art landscape, success hinges on demonstrating and maintaining the inventive step of the specific invention.
Key Takeaways
- The patent’s claims protect specific drug combinations and their therapeutic uses, with scope defined by the composition ratios and formulations.
- The landscape in Brazil emphasizes a balance between innovative combination therapies and existing prior art; patent challengers need to scrutinize specificity.
- Multi-layered patent protection, including composition, use, and method claims, offers a robust strategic advantage.
- Companies should monitor similar patents and publications to navigate around potential infringements or to strengthen their own patent filings.
- Understanding local legal standards and prior art is crucial for patent enforcement and for positioning new innovations.
FAQs
Q1: How does Brazil’s patent law impact the scope of pharmaceutical patents like BRPI0923403?
A1: Brazil’s law requires that pharmaceutical patents demonstrate novelty and inventive step. Claims must be clearly supported by the description, and scope is limited by prior art. Overly broad claims risk invalidation if prior art renders them obvious.
Q2: Can a generic manufacturer challenge BRPI0923403 after expiry?
A2: Yes. Once the patent expires, generic manufacturers can produce similar formulations, provided they do not infringe remaining patent claims or perform licensing negotiations if applicable.
Q3: How does the scope of use claims influence potential infringement?
A3: Use claims extend patent protection to specific therapeutic methods. Infringement occurs if a third party performs the claimed method or directly or indirectly uses the patented composition for the protected indication.
Q4: Are combination drug patents in Brazil enforceable if the components are well-known?
A4: Enforcement depends on demonstrating that the specific combination, ratios, or use involves an inventive step over prior knowledge. Generic challenges often focus on obviousness.
Q5: How important is claim drafting quality in maintaining patent validity?
A5: Extremely. Precise, well-supported claims that clearly define inventive features reduce vulnerability to invalidation and improve enforceability.
Sources:
[1] INPI Patent Database, BRPI0923403 patent documentation.
[2] Brazilian Industrial Property Law (Law No. 9,279/1996).
[3] WIPO Patent Scope Database, global landscape of combination therapy patents.
[4] Scientific publications on drug combination therapies relevant to the patent’s scope.
